Hypofractionated Radiation Therapy in the Treatment of Early-Stage Breast Cancer
- 306 Downloads
Hypofractionated radiation refers to the use of fewer, larger-dose radiation treatments that are usually given over a shorter time period compared to conventional radiation fraction sizes. Randomized trials of hypofractionated whole breast irradiation (WBI) have demonstrated comparable outcomes as conventional fractionation. For a higher-risk population for local recurrence, a phase 3 trial by the Radiation Therapy Oncology Group (RTOG) is currently studying hypofractionated WBI with a concurrent tumor bed boost over 3 weeks. Accelerated partial breast irradiation limits radiation to the region of the tumor bed for 1–3 weeks and is the subject of an ongoing randomized trial by the National Surgical Breast and Bowel Project and RTOG. Questions remain for hypofractionation about optimal patient selection, radiation techniques, and the risk of late toxicity. But results from current trials could make hypofractionation more widely accepted for patients with early-stage breast cancer.
KeywordsBreast cancer Radiation therapy Hypofractionation Radiation fractionation Breast boost
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf [accessed November 1, 2010].
- 4.Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27(15):2466–73.PubMedCrossRefGoogle Scholar
- 6.Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;366(9503):2087–106.Google Scholar
- 10.• The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371: 1098–107. A randomized trial showing equivalence of 3-week hypofractionated and 5-week standard fractionated whole-breast radiation. CrossRefGoogle Scholar
- 11.• Whelan TJ, Pignol J-P, Levine MN, et al. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. N Engl J Med 2010;362(6): 513–20. Ten-year results of a randomized trial showing equivalence of 3-week hypofractionated and 5-week standard fractionated whole-breast radiation. PubMedCrossRefGoogle Scholar
- 13.Bartelink H, Horiot J-C, Poortmans PM, et al. Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881–10882 Trial. J Clin Oncol. 2007;25:3259–65.PubMedCrossRefGoogle Scholar
- 15.Fisher J, Scott C, Stevens R, et al. Randomized phase III study comparing best supportive care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97–13. Int J Radiat Oncol Biol Phys. 2000;48:1307–10.PubMedCrossRefGoogle Scholar
- 20.•• Smith BD, Bentzen SM, Correa CR, et al. Fractionation for Whole Breast Irradiation: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Int J Radiat Oncol Biol Phys 2010. A review of the evidence and consensus statement on the current use of whole-breast hypofractionation. Google Scholar
- 28.Smith TE, Lee D, Turner BC, Carter D, Haffty B. True recurrence vs. new primary ipsilateral breast tumor relapse: An analysis of clinical and pathologic differences and their implications in natural history, prognosis, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000;48:1281–9.PubMedCrossRefGoogle Scholar
- 31.• Vicini F, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2011;79(3): 808–17. The largest published series of accelerated partial breast irradiation. PubMedCrossRefGoogle Scholar
- 34.• Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma--5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 2007;69(3): 694–702. A randomized trial showing equivalence of accelerated partial breast irradiation and whole breast irradiation. PubMedCrossRefGoogle Scholar
- 37.Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64(2):489–95.PubMedCrossRefGoogle Scholar
- 38.Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2007;69(4):1124–30.PubMedCrossRefGoogle Scholar
- 39.•• Smith BD, Arthur DW, Buchholz TA, et al. Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009;74(4): 987–1001. A review of the evidence and consensus statement on the current use of accelerated partial breast irradiation. PubMedCrossRefGoogle Scholar
- 40.•• Polgar C, Van Limbergen E, Potter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol 2010;94(3): 264–73. A review of the evidence and consensus statement on the current use of accelerated partial breast irradiation. PubMedCrossRefGoogle Scholar
- 41.Julian TB. Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. J Clin Oncol. 2011;29(15S):82s.Google Scholar